Publication | Closed Access

HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

Breast OncologySingle-agent DocetaxelMedicinePathologySingle-agent DoxorubicinBreast CancerPharmacotherapyPredictive MarkerCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer